(Q38510908)

3 September 2017

title

ERK activation by thymosin-beta-4 (TB4) overexpression induces paclitaxel-resistance (English)

1 reference

3 September 2017

1 reference

5

Young-Il Yeom

1 reference

3 September 2017

Su-Young Oh

1

1 reference

3 September 2017

Ji-Hee Song

2

1 reference

3 September 2017

Jung-Eun Gil

3

1 reference

3 September 2017

Jeong-Hee Kim

4

1 reference

3 September 2017

Eun-Yi Moon

6

1 reference

3 September 2017

language of work or name

English

0 references

publication date

3 March 2006

1 reference

Experimental Cell Research

3 September 2017

published in

1 reference

3 September 2017

volume

312

1 reference

3 September 2017

issue

9

1 reference

3 September 2017

page(s)

1651-1657

1 reference

beta-Thymosins, small acidic peptides with multiple functions

3 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.01.030

Complete amino acid sequence of bovine thymosin beta 4: a thymic hormone that induces terminal deoxynucleotidyl transferase activity in thymocyte populations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.01.030

Thymosin beta4 is released from human blood platelets and attached by factor XIIIa (transglutaminase) to fibrin and collagen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.01.030

Coupling of folding and binding of thymosin beta4 upon interaction with monomeric actin monitored by nuclear magnetic resonance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.01.030

The beta-thymosin/WH2 domain; structural basis for the switch from inhibition to promotion of actin assembly

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.01.030

Control of actin dynamics by proteins made of beta-thymosin repeats: the actobindin family

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.01.030

Thymosin beta 4 stimulates directional migration of human umbilical vein endothelial cells

7 January 2021

2 references

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.01.030

7 January 2021

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.01.030

inferred from DOI database lookup

7 January 2021

based on heuristic

Thymosin beta4 accelerates wound healing.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.01.030

Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.01.030

Role of thymosin beta4 in tumor metastasis and angiogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.01.030

Thymosin beta4: a new molecular target for antitumor strategies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.01.030

The actin binding site on thymosin β4promotes angiogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.01.030

Thymosin-beta4 inhibits corneal epithelial cell apoptosis after ethanol exposure in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.01.030

Thymosin beta4 promotes angiogenesis, wound healing, and hair follicle development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.01.030

Overexpression of the thymosin beta-4 gene is associated with increased invasion of SW480 colon carcinoma cells and the distant metastasis of human colorectal carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.01.030

Decreased thymosin beta4 in apoptosis induced by a variety of antitumor drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.01.030

Microtubules as a target for anticancer drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.01.030

Rapid colorimetric assay for cell growth and survival. Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.01.030

The role of ERK 1/2 and p38 MAP-kinase pathways in taxol-induced apoptosis in human ovarian carcinoma cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.01.030

ERK inhibitor PD98059 enhances docetaxel-induced apoptosis of androgen-independent human prostate cancer cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.01.030

Synergistic induction of tumor cell apoptosis by death receptor antibody and chemotherapy agent through JNK/p38 and mitochondrial death pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.01.030

Down-regulation of Raf-1 kinase is associated with paclitaxel resistance in human breast cancer MCF-7/Adr cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.01.030

NF-kB signaling blockade abolishes implant particle-induced osteoclastogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.01.030

Serine protease inhibitor TPCK prevents Taxol-induced cell death and blocks c-Raf-1 and Bcl-2 phosphorylation in human breast carcinoma cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.01.030

Cell death by mitotic catastrophe: a molecular definition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.01.030

DNA damage-induced apoptosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.01.030

10.1016/J.YEXCR.2006.01.030

7 January 2021

Identifiers

DOI

1 reference

3 September 2017

1 reference